Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).
出版信息
Aust Prescr. 2025 Jun;48(3):107-108. doi: 10.18773/austprescr.2025.024.
Abstract
摘要
相似文献
1
Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).司美格鲁肽用于降低超重或肥胖但无糖尿病患者的心血管风险（新适应症）。
Aust Prescr. 2025 Jun;48(3):107-108. doi: 10.18773/austprescr.2025.024.
2
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
3
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.司美格鲁肽2.4毫克对肥胖或超重且患有心血管疾病患者的人群水平影响：一项基于SELECT试验的建模研究
Diabetes Obes Metab. 2025 Jun;27(6):3442-3452. doi: 10.1111/dom.16370. Epub 2025 Apr 4.
4
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.在非糖尿病肥胖患者中，司美格鲁肽用于减肥的疗效和安全性：系统评价和荟萃分析。
J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23.
5
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.根据SGLT2i使用情况，口服司美格鲁肽与2型糖尿病患者心血管结局：SOUL随机试验的预设分析
Circulation. 2025 Jun 10;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545. Epub 2025 Mar 29.
6
A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.一项关于每周一次司美格鲁肽用于限制超重/肥胖吸烟者戒烟后体重增加的随机对照试验：研究方案。
Contemp Clin Trials. 2025 Aug;155:107989. doi: 10.1016/j.cct.2025.107989. Epub 2025 Jun 18.
7
Wegovy (semaglutide): a new weight loss drug for chronic weight management.韦格利（司美格鲁肽）：一种用于慢性体重管理的新型减肥药。
J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27.
8
Factors Associated With Semaglutide Initiation Among Adults With Obesity.肥胖成年人中与司美格鲁肽起始治疗相关的因素。
JAMA Netw Open. 2025 Jan 2;8(1):e2455222. doi: 10.1001/jamanetworkopen.2024.55222.
9
Clinical review of subcutaneous semaglutide for obesity.皮下司美格鲁肽治疗肥胖的临床综述。
J Clin Pharm Ther. 2022 Feb;47(2):184-193. doi: 10.1111/jcpt.13574. Epub 2021 Dec 28.
10
Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months).司美格鲁肽2.4毫克用于肥胖或超重患者的长期临床结局：美国一项真实世界回顾性队列研究（SCOPE 12个月）
Postgrad Med. 2025 Apr-May;137(3-4):251-260. doi: 10.1080/00325481.2025.2482274. Epub 2025 Mar 27.
本文引用的文献
1
National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025.澳大利亚国家心脏基金会与澳大利亚和新西兰心脏学会：《2025年澳大利亚急性冠状动脉综合征诊断与管理综合临床指南》
Heart Lung Circ. 2025 Apr;34(4):309-397. doi: 10.1016/j.hlc.2025.02.102.
2
As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging.随着司美格鲁肽的人气飙升，罕见但严重的不良反应正在出现。
JAMA. 2023 Dec 12;330(22):2140-2142. doi: 10.1001/jama.2023.16620.
3
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
Zotero 插件